Veracyte (VCYT) Q3 2026 earnings review
Veracyte cuts its testing plan as prostate volume misses targets
Veracyte, a maker of genomic cancer tests, saw its main prostate franchise slow while its thyroid and breast tests gained ground. Total revenue rose 15% to $152 million, but chief executive Marc Stapley acknowledged that Decipher Prostate test volume fell short of the company's plan. Stapley cut the full-year testing revenue outlook, which by our math leaves fourth-quarter testing growth slowing to about 7%.
| Testing revenue | $146.4M +15% from a year ago |
|---|---|
| Decipher Prostate volume | ~29,900 ~31,000 planned (+12% YoY) |
| Profit per share, excluding one-offs | $0.51 0% from a year ago |
| Full-year testing revenue outlook | Cut $7M middle of the range: 16% growth |
⚖️ Verdict: 🔴 Bearish
The story got worse because Decipher Prostate missed its volume target and forced the first outlook cut in two years, while doubling research costs stopped profit margin expansion. On the positive side, the company secured U.S. Medicare coverage for its Prosigna breast cancer test and put its cash pile to work through a bladder-test acquisition and a $100 million buyback plan.
The question now is whether Decipher's slowdown is a brief pause in low-risk prostate testing or the start of slower growth across its core urology market. Either hospital ordering rebounds in the fourth quarter and new breast and bladder tests pick up the slack in 2027, or higher research spending squeezes profits as the main growth driver matures. Next quarter's Decipher volume and the initial 2027 revenue outlook will settle it.
🐂 Bull Case
Medicare Covered Prosigna and Overseas Kit Sales Jumped
Prosigna is Veracyte's test for estimating whether early-stage breast cancer will return. Entering the quarter, a primary risk was that the U.S. laboratory version lacked Medicare coverage, leaving the company to absorb test costs without collecting revenue. This quarter, the cancer diagnostics group secured Medicare coverage for Prosigna in the U.S., removing that reimbursement hurdle.
Overseas, hospitals run Prosigna on their own machines using test kits they buy from the South San Francisco company. That product revenue rose 40.1% from a year ago to $4.6 million, lifted by "strong adoption of Prosigna IVD following the release of the phase III OPTIMA trial results at ASCO". Even so, the updated 2026 outlook still expects "minimal revenue contribution from recently launched tests".
What to watch: the final Medicare payment rate for Prosigna and its inclusion in the 2027 revenue outlook next quarter. A payment rate near $2,500 per test would allow U.S. breast testing to contribute meaningful revenue next year.
Afirma Thyroid Revenue Accelerated on Higher Test Prices
Afirma, a genomic test that helps doctors decide whether a thyroid nodule is cancerous, carried the top line this quarter. Chief executive Marc Stapley noted that "Afirma outperformed", with revenue climbing 19.2% from a year ago to $51.5 million on 12.4% test volume growth to about 19,100 tests.
Because revenue grew nearly seven percentage points faster than test volume, the average price collected per Afirma test rose by about 6% by our math. That price gain helped keep blended testing revenue per test at $2,958, up 1.1% from a year ago by our math, even as higher-priced prostate tests grew more slowly.
What to watch: Afirma revenue growth in the fourth quarter and the 2027 outlook. Management previously warned that one-time billing recoveries and a technical fix that reduced inconclusive test results this year will create a tougher comparison in 2027.
Veracyte Bought a Bladder Test Maker and Approved Buybacks
For more than a year, cash accumulated on the balance sheet while management declined calls to return capital. This quarter, the company put that cash to work on two fronts. It spent $153.2 million net of cash acquired to buy deals, and its board approved a 12-month share repurchase program for up to $100 million.
The company acquired Convergent Genomics, "expanding our urology portfolio with a urinary tumor DNA testing platform to help guide bladder cancer care across the patient journey". Combined with the recently launched TrueMRD blood test for muscle-invasive bladder cancer, the deal gives the urology sales force a broader set of bladder tests alongside its flagship prostate product.
What to watch: share repurchases executed in the fourth quarter and any 2027 revenue targets for Convergent Genomics. Buying back stock would begin to offset a diluted share count that rose 3.9% from a year ago.
🐻 Bear Case
Decipher Prostate Missed Plan and Triggered a Testing Cut
Decipher Prostate, a genomic test that scores how likely a prostate tumor is to spread, drives nearly two-thirds of testing sales. Three months ago, management projected about 31,000 Decipher tests for the third quarter and 33,000 for the fourth. Instead, "Decipher Prostate volume was below our expectations", Stapley said, landing at about 29,900 tests.
- Decipher Prostate volume: ~29,900 tests, up 12.0% from a year ago and up only 200 tests from last quarter
- Decipher Prostate revenue: $92.3 million, up 12.3% from a year ago vs 20.0% growth last quarter
- Full-year testing revenue outlook: cut by $7 million at the middle of the range to $571–573 million
- Fourth-quarter testing revenue growth: 6.6% from a year ago implied by the new outlook, down from 14.6% in Q3
After fifteen straight quarters of 20%-plus volume growth through early 2026, Decipher volume growth has slowed to 17.0% in the second quarter and 12.0% in the third. Although the company added new clinical studies supporting Decipher in intermediate and very high-risk patients, cutting the full-year testing plan shows the slowdown will persist through year-end.
What to watch: fourth-quarter Decipher test volume against the prior 33,000 target. A second straight quarter of small sequential gains would show that prostate test adoption is maturing faster than management planned.
Research Spending Doubled and Stopped Profit Growth
Expanding profit margins were a primary pillar of the bull case through the first half of 2026. In the third quarter, that operating leverage reversed even though gross margin, excluding one-offs, rose 0.9 percentage points to 73.7%. Total operating expenses, excluding one-offs, jumped 24.3% from a year ago to $72.9 million, outpacing the 15.1% revenue increase.
Research and development caused the surge, doubling from $16.0 million a year ago to $32.2 million (or from 12.1% to 21.2% of sales). Even after stripping out stock pay and deal costs, research spending climbed 8.6 percentage points of revenue, more than offsetting a 5.2-point drop in general and administrative overhead. As a result, Adjusted EBITDA margin fell 2.9 percentage points to 27.2%, and profit per share excluding one-offs stayed flat at $0.51. Reported net income of $31.5 million got a one-time boost from a $10.4 million tax benefit.
What to watch: research and development spending in the fourth quarter now that Convergent Genomics is on the books. Continued spending above 20% of sales while testing growth slows will keep annual profit margins from expanding.
Risks this quarter didn't answer
Several standing concerns cannot be evaluated from the earnings release alone and await the conference call or the quarterly filing.
- Prior-period cash collections: the release did not state how much revenue came from old bills, so underlying test pricing ex-collections is not yet readable.
- New test volumes: management still expects minimal revenue from Prosigna LDT and TrueMRD this year and gave no test counts for either launch.
- Low-risk prostate and AI competition: the release did not break out low-risk Decipher volume or address competition from digital pathology tools.
- OPTIMA trial publication: the timing of the independent journal publication needed to get Prosigna into U.S. clinical guidelines remains unstated.
- Patent litigation: non-GAAP adjustments included $3.2 million for legal proceedings, with no update on the Sonic Healthcare patent reexamination ahead of the Q1 2027 trial.
💲 Other KPIs
Cash and short-term investments fell by $114.7 million from last quarter because Veracyte spent $153.2 million in net cash to buy businesses, including Convergent Genomics. Operations generated $40.3 million in cash during the quarter, leaving about $37.9 million in free cash flow after $2.3 million of equipment purchases by our math.
Uncollected customer bills rose 18.7% from a year ago and 4.8% from last quarter, outpacing the 15.1% year-over-year revenue growth. Working capital tied up in receivables has absorbed $12.0 million of operating cash over the first nine months of 2026, compared with $3.9 million in the same period last year.
Diluted shares rose 3.9% from a year ago as employee stock awards vested and options were exercised. Stock-based compensation totaled $14.0 million in the quarter, up 29.8% from a year ago. The newly authorized $100 million buyback program gives the diagnostics maker a tool to slow this dilution.
🔮 Guidance
Cut. Veracyte trimmed the top end of its full-year revenue plan by $3 million, lowering the middle of the range by $1.5 million to 14.4% growth. By our math, that leaves $150.4 million for the fourth quarter, or 6.9% growth from a year ago — less than half the 15.1% pace in Q3. This breaks a streak of two raises earlier this year (+$11M in Q1, +$6M in Q2).
Cut. The company lowered its core testing revenue outlook by $7 million at the middle of the range to 16.0% growth, following the third-quarter volume shortfall in Decipher Prostate. By our math, the new range implies fourth-quarter testing revenue of $144.8 million, or 6.6% growth from a year ago and a 1.1% drop from Q3.
Unchanged. Management kept its full-year Adjusted EBITDA margin floor at greater than 26%. Because the margin ran at 29.0% across the first nine months, hitting the 26% floor would allow the fourth-quarter margin to drop as low as 17.2% by our math, leaving a wide cushion even with higher research spending.
❓ Key Questions
Why did Decipher Prostate volume miss the 31,000 target?
Decipher added only 200 tests from last quarter to reach 29,900, missing the ~31,000 plan and driving a $7 million testing outlook cut. Investors need to know whether low-risk prostate testing fell further or if high-risk ordering also slowed.
How much did prior-period collections add to Q3 testing revenue?
Collections on tests from prior years added $4.5 million in Q2 and $4.2 million in Q1. The Q3 release omitted this figure, which is needed to check whether underlying test prices held near $2,900.
What drove the $16 million jump in R&D spending?
Research and development expenses doubled from a year ago to $32.2 million, pulling Adjusted EBITDA margin down nearly 3 points. Management did not say how much of this step-up is recurring versus tied to clinical trials or the Convergent deal.
What are the revenue and cost terms of Convergent Genomics?
The company paid $153.2 million in net cash and booked $23.1 million in new contingent consideration liabilities this year, but disclosed no current revenue, test volume, or annual burn rate for the acquired bladder cancer business.
What Medicare price was set for Prosigna Breast ROR?
Securing U.S. Medicare coverage for Prosigna was a major milestone, but the release did not state the approved payment rate per test or how many U.S. hospitals have begun ordering since the June launch.